The cellular and molecular basis of bitter tastant-induced bronchodilation
| dc.contributor.author | Zhang, Cheng-Hai | |
| dc.contributor.author | Lifshitz, Lawrence M. | |
| dc.contributor.author | Uy, Karl | |
| dc.contributor.author | Ikebe, Mitsuo | |
| dc.contributor.author | Fogarty, Kevin E. | |
| dc.contributor.author | ZhuGe, Ronghua | |
| dc.date | 2022-08-11T08:08:29.000 | |
| dc.date.accessioned | 2022-08-23T15:56:38Z | |
| dc.date.available | 2022-08-23T15:56:38Z | |
| dc.date.issued | 2013-03-05 | |
| dc.date.submitted | 2013-07-26 | |
| dc.identifier.citation | <p>PLoS Biol. 2013;11(3):e1001501. doi: 10.1371/journal.pbio.1001501. <a href="http://dx.doi.org/10.1371/journal.pbio.1001501">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 1544-9173 (Linking) | |
| dc.identifier.doi | 10.1371/journal.pbio.1001501 | |
| dc.identifier.pmid | 23472053 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/30013 | |
| dc.description.abstract | Bronchodilators are a standard medicine for treating airway obstructive diseases, and beta2 adrenergic receptor agonists have been the most commonly used bronchodilators since their discovery. Strikingly, activation of G-protein-coupled bitter taste receptors (TAS2Rs) in airway smooth muscle (ASM) causes a stronger bronchodilation in vitro and in vivo than beta2 agonists, implying that new and better bronchodilators could be developed. A critical step towards realizing this potential is to understand the mechanisms underlying this bronchodilation, which remain ill-defined. An influential hypothesis argues that bitter tastants generate localized Ca(2+) signals, as revealed in cultured ASM cells, to activate large-conductance Ca(2+)-activated K(+) channels, which in turn hyperpolarize the membrane, leading to relaxation. Here we report that in mouse primary ASM cells bitter tastants neither evoke localized Ca(2+) events nor alter spontaneous local Ca(2+) transients. Interestingly, they increase global intracellular [Ca(2+)]i, although to a much lower level than bronchoconstrictors. We show that these Ca(2+) changes in cells at rest are mediated via activation of the canonical bitter taste signaling cascade (i.e., TAS2R-gustducin-phospholipase Cbeta [PLCbeta]- inositol 1,4,5-triphosphate receptor [IP3R]), and are not sufficient to impact airway contractility. But activation of TAS2Rs fully reverses the increase in [Ca(2+)]i induced by bronchoconstrictors, and this lowering of the [Ca(2+)]i is necessary for bitter tastant-induced ASM cell relaxation. We further show that bitter tastants inhibit L-type voltage-dependent Ca(2+) channels (VDCCs), resulting in reversal in [Ca(2+)]i, and this inhibition can be prevented by pertussis toxin and G-protein betagamma subunit inhibitors, but not by the blockers of PLCbeta and IP3R. Together, we suggest that TAS2R stimulation activates two opposing Ca(2+) signaling pathways via Gbetagamma to increase [Ca(2+)]i at rest while blocking activated L-type VDCCs to induce bronchodilation of contracted ASM. We propose that the large decrease in [Ca(2+)]i caused by effective tastant bronchodilators provides an efficient cell-based screening method for identifying potent dilators from among the many thousands of available bitter tastants. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23472053&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.rights | Copyright: 2013 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
| dc.subject | Amino Acids, Peptides, and Proteins | |
| dc.subject | Animal Experimentation and Research | |
| dc.subject | Cells | |
| dc.subject | Cellular and Molecular Physiology | |
| dc.subject | Chemical Actions and Uses | |
| dc.subject | Chemicals and Drugs | |
| dc.subject | Investigative Techniques | |
| dc.subject | Molecular Biology | |
| dc.subject | Pharmaceutical Preparations | |
| dc.subject | Respiratory System | |
| dc.subject | Respiratory Tract Diseases | |
| dc.subject | Therapeutics | |
| dc.title | The cellular and molecular basis of bitter tastant-induced bronchodilation | |
| dc.type | Journal Article | |
| dc.source.journaltitle | PLoS biology doi:10.1371/annotation/7899a865-d68b-45bd-8b9b-ec6f50c9308a | |
| dc.source.volume | 11 | |
| dc.source.issue | 3 | |
| dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1246&context=faculty_pubs&unstamped=1 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/faculty_pubs/247 | |
| dc.identifier.contextkey | 4352258 | |
| refterms.dateFOA | 2022-08-23T15:56:38Z | |
| html.description.abstract | <p>Bronchodilators are a standard medicine for treating airway obstructive diseases, and beta2 adrenergic receptor agonists have been the most commonly used bronchodilators since their discovery. Strikingly, activation of G-protein-coupled bitter taste receptors (TAS2Rs) in airway smooth muscle (ASM) causes a stronger bronchodilation in vitro and in vivo than beta2 agonists, implying that new and better bronchodilators could be developed. A critical step towards realizing this potential is to understand the mechanisms underlying this bronchodilation, which remain ill-defined. An influential hypothesis argues that bitter tastants generate localized Ca(2+) signals, as revealed in cultured ASM cells, to activate large-conductance Ca(2+)-activated K(+) channels, which in turn hyperpolarize the membrane, leading to relaxation. Here we report that in mouse primary ASM cells bitter tastants neither evoke localized Ca(2+) events nor alter spontaneous local Ca(2+) transients. Interestingly, they increase global intracellular [Ca(2+)]i, although to a much lower level than bronchoconstrictors. We show that these Ca(2+) changes in cells at rest are mediated via activation of the canonical bitter taste signaling cascade (i.e., TAS2R-gustducin-phospholipase Cbeta [PLCbeta]- inositol 1,4,5-triphosphate receptor [IP3R]), and are not sufficient to impact airway contractility. But activation of TAS2Rs fully reverses the increase in [Ca(2+)]i induced by bronchoconstrictors, and this lowering of the [Ca(2+)]i is necessary for bitter tastant-induced ASM cell relaxation. We further show that bitter tastants inhibit L-type voltage-dependent Ca(2+) channels (VDCCs), resulting in reversal in [Ca(2+)]i, and this inhibition can be prevented by pertussis toxin and G-protein betagamma subunit inhibitors, but not by the blockers of PLCbeta and IP3R. Together, we suggest that TAS2R stimulation activates two opposing Ca(2+) signaling pathways via Gbetagamma to increase [Ca(2+)]i at rest while blocking activated L-type VDCCs to induce bronchodilation of contracted ASM. We propose that the large decrease in [Ca(2+)]i caused by effective tastant bronchodilators provides an efficient cell-based screening method for identifying potent dilators from among the many thousands of available bitter tastants.</p> | |
| dc.identifier.submissionpath | faculty_pubs/247 | |
| dc.contributor.department | Biomedical Imaging Group | |
| dc.contributor.department | Program in Molecular Medicine | |
| dc.contributor.department | Department of Microbiology and Physiological Systems | |
| dc.contributor.department | Department of Surgery | |
| dc.source.pages | e1001501 |
